MXPA02008038A - 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas subtituidas y su uso para inhibir lipasa sensible a hormona. - Google Patents

3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas subtituidas y su uso para inhibir lipasa sensible a hormona.

Info

Publication number
MXPA02008038A
MXPA02008038A MXPA02008038A MXPA02008038A MXPA02008038A MX PA02008038 A MXPA02008038 A MX PA02008038A MX PA02008038 A MXPA02008038 A MX PA02008038A MX PA02008038 A MXPA02008038 A MX PA02008038A MX PA02008038 A MXPA02008038 A MX PA02008038A
Authority
MX
Mexico
Prior art keywords
substituted
alkyl
aryl
cycloalkyl
oxdiazol
Prior art date
Application number
MXPA02008038A
Other languages
English (en)
Inventor
Stefan Petry
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000110968 external-priority patent/DE10010968A1/de
Priority claimed from DE2001102265 external-priority patent/DE10102265C1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA02008038A publication Critical patent/MXPA02008038A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/1131,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La invencion se refiere a 3-fenil-5-alcoxi-1,3,4- oxadiazol-2-onas de la formula (I), (ver formula) en donde R1 significa alquilo con 1 a 6 atomos de carbono substituido y cicloalquilo con 3 a 9 atomos de carbono, R2, R3, R4 y R5 significan hidrogeno, halogeno, nitro, alquilo con 1 a 4 atomos de carbono, alquiloxi con 1 a 9 atomos de carbono, arilo con 6 a 10 atomos de carbono-alquiloxi con 1 a 4 atomos de carbono substituido, ariloxi con 6 a 10 atomos de carbono, arilo con 6 a 10 atomos de carbono, cicloalquilo con 3 a 8 atomos de carbono o O-cicloalquilo con 3 a 8 atomos de carbono o 2-oxo-pirrolidin-1-ilo, 2,5- dimetilpirrol-1-ilo o NR6-A-R7. en la condicion de que R2, R3, R4 y R5 no significan simultaneamente hidrogeno y al menos uno de los radicales R2, R3, R4 o R5 representa el radical 2-oxo-pirrolidin-1-ilo, 2,5-dimetilpirrol-1-ilo o NR6-A-R7, con R6 = hidrogeno, alquilo con 1 a 4 atomos de carbono o arilo con 6 a 10 atomos de carbono-alquilo con 1 a 4 atomos de carbono substituido, A = un solo enlace, COn, SOn, o CONH, n = 1 o 2, R7 = hidrogeno, alquilo con 1 a 18 atomos de carbono substituido, alquenilo con 2 a 18 atomos de carbono, arilo con 6 a 10 atomos de carbono-alquilo con 1 a 4 atomos de carbono, cicloalquilo con 5 a 8 atomos de carbono-alquilo con 1 a 4 atomos de carbono, cicloalquilo con 5 a 8 atomos de carbono, arilo con 6 a 10 atomos de carbono-alquenilo con 2 a 6 atomos de carbono, arilo con 6 a 10 atomos de carbono, difenilo, difenil-alquilo con 1 a 4 atomos de carbono, indanilo o el grupo Het-(CH2), con r = 0, 1, 2 o 3 y Het = un heterociclo de 5 a 7 miembros saturado e insaturado que puede estar benzoanelado y substituido. La invencion tambien se refiere a un metodo para producir los mismos. Los compuestos de la invencion tienen efecto inhibitorio en lipasa sensible a hormona, HSL.
MXPA02008038A 2000-03-07 2001-02-20 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas subtituidas y su uso para inhibir lipasa sensible a hormona. MXPA02008038A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000110968 DE10010968A1 (de) 2000-03-07 2000-03-07 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE2001102265 DE10102265C1 (de) 2001-01-18 2001-01-18 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
PCT/EP2001/001898 WO2001066531A1 (de) 2000-03-07 2001-02-20 Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase

Publications (1)

Publication Number Publication Date
MXPA02008038A true MXPA02008038A (es) 2004-04-05

Family

ID=26004720

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008038A MXPA02008038A (es) 2000-03-07 2001-02-20 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas subtituidas y su uso para inhibir lipasa sensible a hormona.

Country Status (28)

Country Link
US (1) US6369088B2 (es)
EP (1) EP1263745B1 (es)
JP (1) JP2003525931A (es)
KR (1) KR100790763B1 (es)
CN (1) CN1261419C (es)
AR (1) AR027611A1 (es)
AT (1) ATE267184T1 (es)
AU (1) AU784827B2 (es)
BR (1) BR0108974A (es)
CA (1) CA2401953A1 (es)
DE (1) DE50102325D1 (es)
DK (1) DK1263745T3 (es)
EE (1) EE04877B1 (es)
ES (1) ES2218383T3 (es)
HK (1) HK1054036B (es)
HR (1) HRP20020732A2 (es)
HU (1) HUP0302772A3 (es)
IL (1) IL151518A (es)
MX (1) MXPA02008038A (es)
NO (1) NO323483B1 (es)
NZ (1) NZ521207A (es)
PL (1) PL359702A1 (es)
PT (1) PT1263745E (es)
RU (1) RU2281283C2 (es)
SK (1) SK12752002A3 (es)
TR (1) TR200401217T4 (es)
WO (1) WO2001066531A1 (es)
YU (1) YU57802A (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6900233B2 (en) 2002-02-28 2005-05-31 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
DE10208987A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE10208986A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
TW201033163A (en) * 2008-10-20 2010-09-16 Sumitomo Chemical Co Method for manufacturing oxadiazolinone compound and intermediate thereof
TW201028406A (en) 2008-12-23 2010-08-01 Bial Portela & Ca Sa 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use
WO2011108724A1 (ja) 2010-03-04 2011-09-09 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JP6007417B2 (ja) * 2011-05-31 2016-10-12 レセプトス エルエルシー 新規glp−1受容体安定剤および調節剤
AU2012352349B2 (en) 2011-12-12 2017-08-17 Receptos Llc Carboxylic acid derivatives comprising four cycles acting as GLP-1 receptor modulators for therapy of diseases such as diabetes
KR102271179B1 (ko) 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 신규의 glp-1 수용체 조절제
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
MX2017000972A (es) 2014-07-25 2017-07-27 Celgene Int Ii Sarl Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
WO2016094729A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN108863774A (zh) * 2018-06-09 2018-11-23 石家庄市绿丰化工有限公司 一种2,4-二氯苯乙酰氯合成的方法
CN113227093A (zh) 2018-11-14 2021-08-06 阿尔塔万特科学公司 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2299328A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Derives de l'alcoyloxy-5 phenyl-3 oxyde azo
US4076824A (en) 1975-02-03 1978-02-28 Rhone-Poulenc Industries Anthelmintic oxadiazolinone derivatives
FR2299028A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Nouvea
DK156439C (da) 1980-09-15 1990-01-22 Shell Int Research 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer
DE3267258D1 (en) 1981-06-15 1985-12-12 Shell Int Research 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates
US5236939A (en) 1989-09-23 1993-08-17 Bayer Aktiengesellschaft Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites
DE3931843A1 (de) 1989-09-23 1991-04-04 Bayer Ag Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents

Also Published As

Publication number Publication date
PT1263745E (pt) 2004-09-30
NO20024201D0 (no) 2002-09-03
WO2001066531A1 (de) 2001-09-13
TR200401217T4 (tr) 2004-06-21
CN1416424A (zh) 2003-05-07
RU2281283C2 (ru) 2006-08-10
JP2003525931A (ja) 2003-09-02
AU784827B2 (en) 2006-06-29
BR0108974A (pt) 2003-06-03
ATE267184T1 (de) 2004-06-15
KR100790763B1 (ko) 2008-01-03
CN1261419C (zh) 2006-06-28
AR027611A1 (es) 2003-04-02
AU3378701A (en) 2001-09-17
EP1263745B1 (de) 2004-05-19
IL151518A0 (en) 2003-04-10
DE50102325D1 (de) 2004-06-24
NO20024201L (no) 2002-09-03
US20010031772A1 (en) 2001-10-18
HUP0302772A2 (hu) 2003-11-28
SK12752002A3 (sk) 2003-04-01
PL359702A1 (en) 2004-09-06
IL151518A (en) 2008-06-05
EP1263745A1 (de) 2002-12-11
US6369088B2 (en) 2002-04-09
NZ521207A (en) 2005-04-29
KR20020079986A (ko) 2002-10-21
HK1054036A1 (en) 2003-11-14
NO323483B1 (no) 2007-05-21
WO2001066531A8 (de) 2002-07-25
ES2218383T3 (es) 2004-11-16
YU57802A (sh) 2005-07-19
HRP20020732A2 (en) 2004-12-31
EE04877B1 (et) 2007-08-15
CA2401953A1 (en) 2001-09-13
EE200200498A (et) 2004-02-16
HUP0302772A3 (en) 2007-03-28
HK1054036B (zh) 2006-11-17
DK1263745T3 (da) 2004-08-16

Similar Documents

Publication Publication Date Title
MXPA02008038A (es) 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas subtituidas y su uso para inhibir lipasa sensible a hormona.
MX9710376A (es) Cetoenoles dialquil-halogenofenilsubstituidos para el empleo como herbicidas y pesticidas.
MY194110A (en) Sioc-based polyethersiloxanes
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
DK1311272T3 (da) Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
ATE334135T1 (de) Metallocene und verfahren zur herstellung von propylenpolymeren
EP1206935A4 (en) TH2 DIFFERENTIAL INHIBITION
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
NO971538L (no) Purin- og guaninforbindelser som inhibitorer for PNP
ATE157969T1 (de) Diaminotrifluoromethylpyrimidinderivate, verfahren zu ihrer herstellung und diese enthaltende phospholipase-a2-inhibitoren
ES2177816T3 (es) Derivados de azahexano como isosteros de sustrato de aspartato proteasas retroviricas.
MX2023010000A (es) Metodo para el control de artropodos da?inos o nematodos da?inos mediante el uso de zoantaminas.
ES2196614T3 (es) Analogos de la 1-3-dihidroxi-20,20-dialquil-vitamina d3.
MXPA04006573A (es) Acidos 3-(imidazolil)-2-alcoxipropanoicos.
FI952848A0 (fi) Epoksialkyyliakrylaattiyhdisteellä oksastetut polypropyleeniaineet
BG101000A (en) Formulaminophenylsulphonyl ureas, methods of oreparing them and their use as herbicides and plant-growth regulators
ES2190130T3 (es) Uretanos derivados de azacicloalcanos, sus analogos tio y ditio, su preparacion y su empleo como inhibidores de 2,3-epoxiescualeno-lanosterol-ciclasa.
DE50211559D1 (en) Hydrophilieadditive
DE69525145T2 (de) Carbamoylmethylharnstoffderivate
ATE236117T1 (de) Radikalabfänger
MX9706627A (es) Derivado de tiazolidinona opticamente activo.
ES2148786T3 (es) Derivados de alfa-hidrazinoacidos y procedimiento para su preparacion.
DE59700694D1 (de) Kraft- und schmierstoffadditive
UA39157C2 (uk) Спосіб одержання похідних 2-арил-3-метил-4-оксо-3,4-дигідрохіназоліну та похідні 7-азабензонорборнену як проміжні сполуки
UY27616A1 (es) Acidos 3 - (amidazolil ) - aminopropanoicos

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status